Cancer Immunotherapeutics Center

Immunotherapy and Drug Development Center

UPMC designed the Immunotherapy and Drug Development Center (IDDC) to speed the most promising new immunotherapies toward large clinical trials.

A diverse team conducts early-phase trials on all aspects of immunotherapy across the spectrum of cancer.

Experts at the IDDC treat solid organ tumors and lymphomas that haven't responded to standard treatment. We leverage UPMC Hillman Cancer Center's science to launch researcher-lead clinical trials.

Through this teamwork, we offer access to treatments never available before and can bring customized care to more people.

To learn more about the IDDC or to make an appointment, contact the IDDC at 412-623-7994 or IDDCreferrals@upmc.edu.

Current Clinical Trials at the IDDC

We're now enrolling people in more than 30 early-phase trials.

These trials address the full range of immunotherapy methods, including:

  • Immune checkpoint antibodies.
  • Small-molecule innate immune agonists.
  • Bispecific immune therapies.
  • Cellular products.
  • Immunometabolism modifiers.

Learn more at the UPMC Hillman Cancer Center Research website.


Experts at the IDDC

Co-Directors: Jason Luke, MD, and Liza Villaruz, MD.

Contact the IDDC

To make a referral or an appointment, contact IDDC at 412-623-7994 or IDDCreferrals@upmc.edu.